Deep Venous Thrombosis
Conditions
Keywords
D-Dimer, DVT, Wells score
Brief summary
Measurement of D-Di (D-Dimer) levels using the in-vitro diagnostic reagent STA® - Liatest® D-Di and STA® - Liatest® D-Di PLUS in plasma samples from patients diagnosed with Deep Vein Thrombosis (DVT) Data from this study may be used in conjunction with data from the prospective study entitled STA® - Liatest® D-Di - Exclusion of Venous Thromboembolism (VTE), NCT01221805, the DiET study,
Interventions
None listed
Sponsors
Diagnostica Stago
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 80 Years
Healthy volunteers
No
Inclusion criteria
* The study population tested will be recruited from ambulatory outpatients (presenting at the emergency unit or outpatient clinic) suspected of having DVT. * Patient is \< 80 years old. * Patient presenting at least one of these symptoms indicative of proximal DVT: leg pain, tenderness (discomfort through palpation), leg swelling and /or edema, * Patient has confirmed proximal DVT by imaging * Low or moderate Wells score * Patient provides written informed consent to participate in the sample collection
Exclusion criteria
* Patient presenting with a condition that may be associated with increased D-dimer levels, even in the absence of VTE, such as: 1. Fibrinolytic therapy within the previous seven (7) days, 2. Bone fracture or surgery (with general anesthesia longer than thirty (30) minutes) within the previous one (1) month, 3. Deep hematoma diagnosed by imaging techniques within the previous one (1) month, 4. Disseminated malignancies and active cancer (active cancer defined as: cancer for which therapeutic or palliative treatment is either ongoing at the time of enrolment or has stopped less than six (6) months before enrolment), 5. Sepsis, severe infections, pneumonia within the previous 1 month, 6. Known liver cirrhosis, 7. Pregnancy or post-partum within the previous 1 month, 8. Atherosclerotic vascular disease thrombosis within the previous 1month (e.g. myocardial infarction, stroke, coronary syndrome, peripheral artery disease stage III or IV), 9. Sickle cell disease, * Patients presenting with a suspect thrombotic event related to catheter implantation * Ongoing therapeutic anticoagulants (curative and preventive treatment) starting twenty four (24) hours or more before the blood drawing for D-dimer testing
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| STA Liatest DDi results in DVT positive cases | At the initial visit (up to 24 hours) | Prospective, ambulatory outpatients (presenting to the emergency unit or outpatient clinic) suspected of having DVT, with a proximal positive imaging results, will be screened for eligibility using the inclusion and exclusion criteria (see Section above). Then the eligible patients will be evaluated using the Wells score and only patient with Low or moderate Pre-Test Probability (PTP) will receive full explanation concerning nature, objectives and risks associated to the participation in this study. Written informed consent will be obtained from each participating subject prior blood drawing, processing, plasma aliquoting and freezing at -80°C for D-Dimer testing (STA Liatest DDi). The whole process, starting from the moment the patient is diagnosed with DVT, should not exceed 24 hours. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| STA Liatest DDi Versus STA Liatest DDi Plus | At the initial visit (up to 24 hours) | Prospective, ambulatory outpatients (presenting to the emergency unit or outpatient clinic) suspected of having DVT, with a proximal positive imaging results, will be screened for eligibility using the inclusion and exclusion criteria (see Section above). Then the eligible patients will be evaluated using the Wells score and only patient with Low or moderate PTP will receive full explanation concerning nature, objectives and risks associated to the participation in this study. Written informed consent will be obtained from each participating subject prior blood drawing, processing, plasma aliquoting and freezing at -80°C for D-Dimer testing (STA Liatest DDi Plus). The whole process, starting from the moment the patient is diagnosed with DVT, should not exceed 24 hours |
Other
| Measure | Time frame | Description |
|---|---|---|
| Plasma bank for DDi measurements | At the initial visit (up to 24 hours) | Prospective, ambulatory outpatients (presenting to the emergency unit or outpatient clinic) suspected of having DVT, with a proximal positive imaging results, will be screened for eligibility using the inclusion and exclusion criteria (see Section above). Then the eligible patients will be evaluated using the Wells score and only patient with Low or moderate PTP will receive full explanation concerning nature, objectives and risks associated to the participation in this study. Written informed consent will be obtained from each participating subject prior blood drawing, processing, plasma aliquoting and freezing at -80°C for D-Dimer testing (STA Liatest DDi or STA Liatest DDi Plus to investigate unmatched results). The whole process, starting from the moment the patient is diagnosed with DVT, should not exceed 24 hours |
Countries
United States
Outcome results
None listed